Comera Life Sciences Holdings, Inc. announced a significant expansion of its SQore(TM) patent portfolio with the issuance of four new patents and two newices of allowance. The six new patents, three issued in the United States and three covering Canada, Korea and India expand the number of proprietary viscosity reducing excipients in Comera's SQore platform and significantly broaden claims covered by previously issued patents. Comera is using its proprietary formulation platform, SQore, to enable subcutaneous (SQ) delivery of intravenous (IV) drugs such as monoclonal antibodies (mAbs).

The addition of excipients, such as caffeine, interrupts intermolecular interactions to reduce viscosity of high concentration mAb formulations. The new issuances and allowed patents broaden the number of SQore excipients covered for viscosity reduction claims, including exclusive rights to certain formulations containing combinations of its proprietary excipients. Additionally, the new patents significantly expand previously issued patent claims to provide exclusive rights on magnitude of viscosity reduction versus control, concentration of protein and quantity of excipient in formulations.

Today's announcement also marks the first issued patent in India, validating Comera's efforts to ensure a broad geographic scope for SQore patent protection.